

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Chowrira et al. Filing Date: October 23, 1993	
		Group: 1645	

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	09/740,332	12/18/00	Blatt et al.			
	*	10/151,116	05/17/02	Matulic-Adamic et al.			
	*	10/201,394	08/13/01	Vargeese et al.			
	*	10/417,012	04/16/03	McSwiggen et al.			
	*	10/422,704	04/24/03	McSwiggen et al.			
	*	10/427,160	04/30/03	Vargeese et al.			
	*	10/444,853	05/23/03	McSwiggen et al.			
	*	10/652,791	08/29/03	McSwiggen et al.			
	*	10/693,059	10/23/03	McSwiggen et al.			
	*	10/720,448	11/24/03	McSwiggen et al.			
	*	10/727,780	12/03/03	Vaish et al.			
	*	60/082,404	04/20/98	Thompson et al.			
	*	60/358,580	02/20/02	Beigelman et al.			
	*	60/362,016	03/06/02	Matulic-Adamic et al.			
	*	60/363,124	03/11/02	Beigelman et al.			
	*	60/386,782	06/06/02	Beigelman et al.			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
		Applicant: Chowrira et al.	
		Filing Date: October 23, 1993	Group: 1645

	*	60/402,996	08/13/02	Usman et al.			
	*	60/406,784	08/29/02	Beigelman et al.			
	*	60/408,378	09/05/02	Beigelman et al.			
	*	60/409,293	09/09/02	Beigelman et al.			
	*	60/440,129	01/15/03	Beigelman et al.			
	*	60/543,480	02/10/04	Jadhavi et al.			
	*	US 2001/0007666	01/05/99	Hoffman et al.			07/12/01
	*	US 2002/0130430	12/29/00	Caster			09/19/02
	*	US 2002/0137210		Churikov			09/26/02
	*	US-2002/0086356	03/30/01	Tuschi et al.			07/04/02
	*	US-2002/0151693	02/08/01	Breaker et al.			10/17/02
	*	US-2003/0059944	09/13/02	Lois-Caballe et al.			03/27/03
	*	US-2003/0206887	09/16/02	Morrissey et al.			11/06/03
	*	US-2004/0019001	07/26/02	McSwiggen et al.			01/29/04
	*	US-2005/0182005	05/13/04	Tuschi et al.			02/18/05
	*	US-2005/0227256	11/26/04	Hulvagner et al.			10/13/05

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
		Applicant: Chowrira et al.	
		Filing Date: October 23, 1993	Group: 1645

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	5,138,045	08/11/98	Cook et al.			
	*	5,214,136	05/25/93	Lin et al.			
	*	5,334,711	08/02/94	Sproat			
	*	5,587,471	12-24-1996	Cook et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,631,360	05/20/97	Usman et al.			
	*	5,670,633	09/23/97	Cook et al.			
	*	5,672,695	09/30/97	Eckstein et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,792,847	08/11/98	Buhr et al.			
	*	5,804,683	09/08/98	Usman et al.			
	*	5,814,620	09/29/98	Robinson et al.			
	*	5,831,071	11/03/98	Usman et al.			
	*	5,854,038	12/29/98	Cech et al.			
	*	5,889,136	03/30/99	Scaringe et al.			
	*	5,898,031	04/27/99	Crooke			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
Applicant: Chowrira et al.		Filing Date: October 23, 1993	Group: 1645

*	5,998,148	12/07/99	Bennett et al.			
*	5,998,203	12/07/99	Adamic et al.			
*	5,998,206	12/07/99	Cowsert			
*	6,001,311	12/14/99	Brennan			
*	6,005,087	12/21/99	Cook et al.			
*	6,008,400	12/28/99	Scaringe et al.			
*	6,054,576	04/25/00	Bellon et al.			
*	6,060,456	05/09/00	Arnold et al.			
*	6,107,094	08/22/00	Crooke			
*	6,111,086	08/29/00	Scaringe et al.			
*	6,117,657	09/12/00	Usman et al.			
*	6,153,737	11/28/00	Manoharan et al.			
*	6,162,909	12/19/00	Bellon et al.			
*	6,180,613	01/30/01	Kaplitt et al.			
*	6,214,805	04-10-2001	Torrence et al.			
*	6,235,310	05/22/01	Wang et al.			
*	6,235,886	05/22/01	Manoharan et al.			
*	6,248,878	06/19/01	Adamic et al.			
*	6,300,074	10/09/01	Gold			

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
Applicant: Chowrira et al.		Filing Date: October 23, 1993	Group: 1645

	*	6,303,773	10/16/01	Bellon et al.			
	*	6,335,434	01/01/02	Guzaev et al.			
	*	6,346,398	02-12-2002	Pavco et al.			
	*	6,353,098	03/05/02	Usman et al.			
	*	6,362,323	03/26/02	Usman et al.			
	*	6,395,713	05/28/02	Beigelman et al.			
	*	6,437,117	08/20/02	Usman et al.			
	*	6,447,796	09/10/02	Vook et al.			
	*	6,469,158	10/22/02	Usman et al.			
	*	6,476,205	11/05/02	Buhr et al.			
	*	6,506,559	06/14/03	Fire et al.			
	*	6,528,631	03/04/03	Cook et al.			
	*	6,573,099	06/03/03	Graham et al.			
	*	6,586,524	07/01/03	Sagara			
	*	6,617,156	09/09/03	Doucette-Stamm et al.			
	*	6,617,156	09/09/03	Doucette-Stam et al.			
	*	6,824,972	11/30/04	Kenwrick et al.			
	*	7,078,196	07-18-2006	Tuschl et al.			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Chowrira et al. Filing Date: October 23, 1993	
		Group: 1645	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclasses	Translation	
							Yes	No
	*	2001240375 (Old Application No. 40375/01)	03/16/01	AU (Graham et al.)				
	*	2,359,180	08/03/00	CA (Kreutzer et al.)				
	*	1144623 B1	01/29/02	EP (Kreutzer et al.)				
	*	08208687	08/13/96	JP (Hotoda et al.)				
	*	89/02439	03/23/89	WO (Arnold et al.)				
	*	90/14090	11/29/90	WO (Gillespie et al.)				
	*	91/03162	03/21/91	WO (Rossi et al.)				
	*	92/07065	04/30/92	WO (Eckstein et al.)				
	*	93/15187	08/05/93	WO (Usman et al.)				
	*	93/23569	11/25/93	WO (Draper et al.)				
	*	94/01550	01/20/94	WO (Agrawal et al.)				
	*	94/02595	02/03/94	WO (Sullivan et al.)				
	*	95/06731	03/09/95	WO (Usman et al.)				
	*	95/11910	05/04/95	WO (Dudycz et al.)				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Chowrira et al. Filing Date: October 23, 1993	
		Group: 1645	

	*	96/10390	04/11/96	WO (Ansell et al.)				
	*	96/10391	04/11/96	WO (Choi et al.)				
	*	96/10392	04/11/96	WO (Holland et al.)				
	*	97/26270	07/24/97	WO (Beigelman et al.)				
	*	98/13526	04/02/98	WO (Woolf et al.)				
	*	99/04819	02/04/99	WO (Klimuk)				
	*	99/05094	02/04/99	WO (Beigelman et al.)				
	*	99/07409	02/18/99	WO (Deschamps de Paillette et al.)				
	*	99/14226	03/25/99	WO (Wengel et al.)				
	*	99/31262	06/24/99	WO (Barry et al.)				
	*	99/32619	07/01/99	WO (Fire et al.)				
	*	99/49029	09/30/99	WO (Graham et al.)				
	*	99/53050	10/21/99	WO (Waterhouse et al.)				
	*	99/54459	10/28/99	WO (Thompson et al.)				
	*	99/61631	12/02/99	WO (Heifetz et al.)				
	*	00/01846	01/13/00	WO (Plaetinck et al.)				
	*	00/17369	03/30/00	WO (Gurney et al.)				
	*	00/44895	08/03/00	WO (Kreutzer et al.)				
	*	00/44914	08/03/00	WO (Li et al.)				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Chowrira et al. Filing Date: October 23, 1993	
		Group: 1645	

*	00/49035	08/24/00	WO (Sheen)				
*	00/53722	09/14/00	WO (O'Hare and Normand)				
*	00/63364	10/26/00	WO (Pachuk et al.)				
*	00/66604	11/09/00	WO (Wengel et al.)				
*	01/04313	01/18/01	WO (Satischandran et al.)				
*	01/29058	04/26/01	WO (Mello et al.)				
*	01/36646	05/25/01	WO (Zernicka-Goetz et al.)				
*	01/38551	05/31/01	WO (Grossniklaus)				
*	01/42443	06/14/01	WO (Churikov et al.)				
*	01/49844	07/12/01	WO (Driscoll et al.)				
*	01/53475	07/26/01	WO (Cogoni et al.)				
*	01/68836	09/20/01	WO (Beach et al.)				
*	01/70944	09/27/01	WO (Honer et al.)				
*	01/70949	09/27/01	WO (Graham et al.)				
*	01/72774	10/04/01	WO (Deak et al.)				
*	01/75164	10/11/01	WO (Tuschl et al.)				
*	01/92513	12/06/01	WO (Arndt et al.)				
*	01/96584	12/20/01	WO (Mushegian et al.)				
*	02/15876	02/28/02	WO (Beigelman et al.)				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
		Applicant: Chowrira et al.	
		Filing Date: October 23, 1993	Group: 1645

	*	02/22636	03/21/02	WO (Bennett et al.)				
	*	02/38805	05/16/02	WO (Echeverri et al.)				
	*	02/44321	06/06/02	WO (Tuschi et al.)				
	*	02/55692	07/18/02	WO (Kreutzer et al.)				
	*	02/55693	07/18/02	WO (Kreutzer et al.)				
	*	02/094185 (PCT/US02/15876)	11/28/02	WO (Beigelman et al.)				
	*	03/005028	02/20/03	WO (McSwiggen et al.)				
	*	03/005346	02/20/03	WO (McSwiggen et al.)				
	*	03/024420	03/27/03	WO (Ahlheim et al.)				
	*	03/044188	05/30/03	WO (Tei et al.)				
	*	03/046185	06/05/03	WO (Wang et al.)				
	*	03/047518	06/12/03	WO (Wang et al.)				
	*	03/064625	08/07/03	WO (Woolf et al.)				
	*	03/064626	08/07/03	WO (Woolf et al.)				
	1.	03/070918	08/28/03	WO (McSwiggen et al.)				
	*	04/013280	02/12/04	WO (Davidson et al.)				
	*	04/048566	11/21/03	WO (Saigo et al.)				
	2.	05/028650	03/31/05	WO (Jadhav et al.)				
	*	05/049821	11/18/04	WO (Naito et al.)				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Chowrira et al.	
(Use several sheets if necessary)			
		Filing Date:	Group:
		October 23, 1993	1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	*	Adah et al., "Chemistry and Biochemistry of 2',5'-Oligoadenylate-Based Antisense Strategy," <i>Current Medicinal Chemistry</i> , 8, 1189-1212 (2001)
	*	Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," <i>Trends Cell Biol.</i> 2:139-144 (1992)
	*	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <i>Nucleic Acids Research</i> 26:4910-4916 (1998)
	3.	Allerson et al., "Fully 2'-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA," <i>J. Med. Chem.</i> , 38:901-904 (2005)
	*	Allshire, "RNAi and Heterochromatin - A Hushed-up Affair," <i>Science</i> 297:1818-1819 (2002)
	*	Anderson et al., "Bispecific short hairpin siRNA constructs targeted to CD4 CXCR4, and CCR5 confer HIV-1 resistance." <i>OGLIGONUCLEOTIDES</i> , vol. 13, no. 5, 2003, pages 303-312, XP002313468, ISSN: 1545-4576, figure 1.
	*	Andrews and Fallor, "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," <i>Nucleic Acids Research</i> 19:2499 (1991)
	*	Baenziger and Fiete, "Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes," <i>Cell</i> 22:611-620 (1980)
	*	Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
		Applicant: Chowrira et al.	
Filing Date: October 23, 1993			Group: 1645

	*	Bannai et al., "Effect of Injection of Antisense of Oligodeoxynucleotides of GAD Isozymes into Rat Ventromedial Hypothalamus on Food Intake and Locomotor Activity," <i>Brain Research</i> 784:305-315 (1998)
	*	Bannai et al., "Water-absorbent Polymer as a Carrier for a Discrete Deposit of Antisense Oligodeoxynucleotides in the Central Nervous System," <i>Brain Research Protocols</i> 3:83-87 (1998)
	*	Bartel and Szostak, "Isolation of New Ribozymes from a Large Pool of Random Sequences," <i>Science</i> 261:1411-1418 (1993)
	*	Basi et al., "Antagonistic Effects of β -Site Amyloid Precursor Protein-cleaving Enzymes 1 and 2 on β -Amyloid Peptide Production in Cells," <i>The Journal of Biological Chemistry</i> , 278, 31512-31520 (2003)
	*	Bass, "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> , 101, 235-238 (2000)
	*	Bass, "The short answer," <i>Nature</i> 411:428-429 (2001)
	*	Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <i>Tetrahedron</i> 49:1925-1963 (1993)
	*	Beaudry and Joyce, "Directed Evolution of an RNA Enzyme," <i>Science</i> 257:635-641 (1992)
	*	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <i>The Journal of Biological Chemistry</i> 270:25702-25708 (1995)
	*	Bellon et al., "4-Thio-oligo- β -D-ribonucleotides: synthesis of β -4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase," <i>Nucleic Acids Research</i> , 21(7):1587-1593 (1993)
	*	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <i>Nucleosides & Nucleotides</i> 16:951-954 (1997)
	*	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <i>Bioconjugate Chem.</i> 8:204-212 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Chowrira et al. Filing Date: October 23, 1993 Group: 1645	

*	Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," <i>Nature</i> 409:363-366 (2001)
*	Bernstein et al., "The rest is silence," <i>RNA</i> , 7:1509-1521 (2001)
*	Bettinger et al., "Size Reduction of Galactosylated PEI/DNA Complexes Improves Lectin-Mediated Gene Transfer into Hepatocytes," <i>Bioconjugate Chem.</i> , 10, 558-561 (1999)
*	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type <u>negative-strand RNA viruses</u> ," <i>BMC Microbiology</i> , 1:34 (2001)
*	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)
*	Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
*	Bongartz et al., "Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide," <i>Nucleic Acids Research</i> 22:4681-4688 (1994)
*	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
*	Braasch et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)
*	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," <i>TIBTECH</i> 12:268-275 (1994)
*	Breaker, "Are engineered proteins getting competition from RNA?" <i>Current Opinion in Biotechnology</i> 7:442-448 (1996)
*	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		Chowrira et al.	
		Filing Date:	Group:
		October 23, 1993	1645

*	Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <u>Neurosurg. Focus</u> 3(5):Article 4 (1997)
*	Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <u>J Neurosurg</u> 88:734-742 (1998)
*	Brody and Gold, "Aptamers as therapeutic and diagnostic agents," <u>Reviews in Molecular Biotechnology</u> 74:5-13 (2000)
*	Buckwold et al., "Effects of a Naturally Occurring Mutation in the Hepatitis B Virus Basal Core Promoter on Precore Cene Expression and Viral Replication," <u>Journal of Virology</u> , 5845-5851 (1996)
*	Burger et al., "Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation," <u>Cornea</u> 4:35-41 (1985/1986)
*	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <u>Biochemistry</u> 35:14090-14097 (1996) (volume no. mistakenly listed as 6)
*	Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," <u>Bioorganic & Medicinal Chemistry</u> 5:1999-2010 (1997)
*	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <u>Methods in Enzymology</u> 211:3-19 (1992)
*	Chiu et al., "siRNA function in RNAi: A chemical modification analysis," <u>RNA</u> , 9:1034-1048 (2003)
*	Choi et al., "Effect of Poly(ethylene glycol) Grafting on Polyethylenimine as a Gene Transfer Vector in vitro," <u>Bull. Korean Chem. Soc.</u> , 22, 46-52 (2001)
*	Chun et al., "Effect of infusion of vasoactive intestinal peptide (VIP)-antisense oligodeoxynucleotide into the third cerebral ventricle above the hypothalamic cuprachiasmatic nucleus on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats," <u>Neuroscience Letters</u> 257:135-138 (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
Applicant: Chowrira et al.		Filing Date: October 23, 1993	Group: 1645

	*	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," <i>Science</i> , 309, 1529-1530 (2005)
	*	Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function," <i>Journal of Interferon and Cytokine Research</i> , 17:503-524 (1997)
	*	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <i>J. Am. Chem. Soc.</i> 113:6324-6326 (1991)
	*	Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," <i>The Journ. of Biol. Chem.</i> 257:939-945 (1982)
	*	Conry et al., "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration," <i>Clinical Cancer Research</i> 5:2330-2337 (1999)
4.		Czauderna et al., "Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells," <i>Nucleic Acids Research</i> , 31(11):2705-2716 (2003)
	*	Czech, Michael P., "MicroRNAs as Therapeutic Targets," <i>The New England Journal of Medicine</i> , 354, 1194-1195 (2006)
	*	d'Aidin et al., "Antisense oligonucleotides to the GluR2 AMPA receptor subunit modify excitatory synaptic transmission in vivo," <i>Molecular Brain Research</i> 55:151-164 (1998)
	*	Database CAPLUS on STN, AN:1992:230597, Segarra et al., "Molecular Characterization of the Enterococcus Faecalis Cytolysin Activator", <i>Infection and Immunity</i> , 1991, Vo. 59, No. 4, pages 1239-46
	*	Diebold et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells," <i>The Journal of Biological Chemistry</i> , 274, 19087-19094 (1999)
	*	Dryden et al., "The lack of specificity of neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus," <i>Journal of Endocrinology</i> 157:169-175 (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Chowrira et al. Filing Date: October 23, 1993 Group: 1645	

*	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <u>Nucleic Acids Research</u> 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser]
*	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <u>Biopolymers</u> 48:39-55 (1998)
*	Edbauer et al., Resenilin and nicastrin regulate each other and determine amyloid β -peptide production via complex formation," <u>PNAS</u> , 99, 8666-8671 (2002)
*	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <u>Methods</u> , 26:199-213 (2002)
*	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <u>Nature</u> 411:494-498 (2001)
*	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <u>The EMBO Journal</u> 20:6877-6888 (2001)
*	Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <u>Genes and Development</u> 15:188-200 (2001)
*	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <u>Delivery Strategies for Antisense Oligonucleotide Therapeutics</u> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
*	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <u>Cell Transplantation</u> 8:47-58 (1999)
*	Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and In Vivo, Using β -Cyclodextrin-Adamantane-Oligonucleotide Conjugates," <u>Antisense and Nucleic Acid Drug Dev.</u> 10:469-478 (2000)
*	Erbacher et al., "Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI), <u>The Journal of Gene Medicine</u> , 1, 210-222 (1999) [sometimes incorrectly cited as pages 1-18]
*	Ferentz and Verdine, "Disulfid Cross-Linked Oligonucleotides," <u>J. Am. Chem. Soc.</u> 113:4000-4002 (1991)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Chowrira et al. Filing Date: October 23, 1993	
		Group: 1645	

	*	Filion and Phillips, "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells," <i>Biochimica et Biophysica Acta</i> 1329:345-356 (1997)
	*	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998)
	*	Fire, "RNA-triggered Gene Silencing," <i>TIG</i> 15:358-363(1999)
	*	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <i>Proc. Natl. Acad. Sci. USA</i> 83:9373-9377 (1986) [sometimes referred to as Frier]
	*	Furgeson et al., "Modified Linear Polyethylenimine—Cholesterol Conjugates for DNA Complexation," <i>Bioconjugate Chem.</i> , 14, 840-847 (2003)
	*	Futami et al., "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002)
	*	GenBank Accession No. AB020693 dated January 10, 2004
	*	GenBank Accession No. AF037412 dated October 8, 1998
	*	GenBank Accession No. AF063658 dated May 16, 1998
	*	GenBank Accession No. AF100308.1 dated March 3, 1999
	*	GenBank Accession No. AJ430458 dated February 12, 2002
	*	GenBank Accession No. D00239 dated February 1, 2000
	*	GenBank Accession No. D11168 dated February 1, 2000
	*	GenBank Accession No. D50483.1 dated February 10, 1999
	*	GenBank Accession No. K02121 dated January 2, 2001
	*	GenBank Accession No. L24917 dated July 14, 1995
	*	GenBank Accession No. L38318 dated November 21, 1995
	*	GenBank Accession No. M16248 dated February 7, 2003
	*	GenBank Accession No. M31724 dated January 8, 1995
	*	GenBank Accession No. NC_001345 dated October 5, 1995

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Chowrira et al.	
(Use several sheets if necessary)		Filing Date: October 23, 1993	Group: 1645

	*	GenBank Accession No. NC_001347 dated September 5, 2006
	*	GenBank Accession No. NC_001353 dated June 26, 2005
	*	GenBank Accession No. NC_001563 dated May 30, 2007
	*	GenBank Accession No. NC_001781 dated March 30, 2006
	*	GenBank Accession No. NM_001285 dated June 27, 2007
	*	GenBank Accession No. NM_001982 dated June 26, 2007
	*	GenBank Accession No. NM_002592.1 dated June 27, 2007
	*	GenBank Accession No. NM_002667 dated February 28, 2007
	*	GenBank Accession No. NM_002737 dated June 27, 2007
	*	GenBank Accession No. NM_003219 dated June 18, 2006
	*	GenBank Accession No. NM_003376.1 dated June 27, 2007
	*	GenBank Accession No. NM_004283 dated November 17, 2006
	*	GenBank Accession No. NM_004448 dated June 29, 2007
	*	GenBank Accession No. NM_005228 dated July 1, 2007
	*	GenBank Accession No. NM_005235 dated June 26, 2007
	*	GenBank Accession No. S82227 dated December 16, 2002
	*	GenBank Accession No. U51188 dated July 7, 2004
	*	GenBank Accession No. U86046 dated February 8, 2002
	*	GenBank Accession No. X01087 dated February 9, 1999
	*	GenBank Accession No. X02316 dated November 14, 2006
	*	GenBank Accession No. X07203 dated September 12, 1993
	*	GenBank Accession No. X60667 dated April 18, 2005
	*	GenBank Accession No. XM_015620 dated February 7, 2002
	*	GenBank Accession No. XM_033884 dated August 1, 2002
	*	GenBank Accession No. XM_067723 dated April 28, 2003

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Chowrira et al.	
(Use several sheets if necessary)		Filing Date: October 23, 1993	Group: 1645

*	Ghirnikar et al., "Chemokine inhibition in rat stab wound brain injury using antisense oligodeoxynucleotides," <i>Neuroscience Letters</i> 247:21-24 (1998)
*	Godbey et al., "Poly(ethylenimine) and its role in gene delivery," <i>Journal of Controlled Release</i> , 60, 149-160 (1999)
*	Godbey et al., "Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> , 96, 5177-5181 (1999)
*	Gold et al., "Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> 64:763-797 (1995)
*	Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," <i>Neuroscience</i> 76:1153-1158 (1997)
*	Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," <i>Bioconjugate Chem.</i> , 10, 1068-1074 (1999)
*	Grant et al., "Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor," <i>Diabetologia</i> 36:282-291 (1993)
*	Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," <i>Science</i> 297:2232-2237 (2002)
*	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> , 543:51-54 (2003)
*	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <i>Science</i> , 286, 950-952 (1999))
*	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in <i>Drosophila</i> Cells," <i>Nature</i> 404:293-296 (2000)
*	Haniu et al., "Characterization of Alzheimer's β -Secretase Protein BACE," <i>The Journal of Biological Chemistry</i> , 275, 21099-21106 (2000)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		Chowrira et al.	
		Filing Date:	Group:
		October 23, 1993	1645

	*	Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," <i>Antisense and Nucleic Acid Drug Development</i> , 13:83-105 (2003)
	*	Hartmann et al., "Spontaneous and Cationic Lipid-Mediated Uptake of Antisense Oligonucleotides in Human Monocytes and Lymphocytes," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 285:920-928 (1998)
	*	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," <i>Science</i> 287:820-825 (2000)
	*	Hofland and Huang, "Formulation and Delivery of Nucleic Acids," <i>Handbook of Exp. Pharmacol.</i> 137:165-192 (1999)
	*	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
	*	Homung et al., "Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)
	*	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in <i>Modern Synthetic Methods</i> ," VCH, 331-417
	*	Hussain et al., "Identification of a Novel Aspartic Protease (Asp 2) as β -Secretase," <i>Molecular and Cellular Neuroscience</i> , 14, 419-427 (1999)
	*	Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," <i>Science</i> 297:2056-2060 (2002)
	*	Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the <i>let-7</i> Small Temporal RNA," <i>Science</i> 293:834-838 (2001)
	*	International Search Report for PCT/US03/04710 mailed November 18, 2003
	*	International Search Report for PCT/US03/05028 mailed October 17, 2003
	*	International Search Report for PCT/US03/05346 mailed October 17, 2003
	*	International Search Report mailed November 19, 2003 for PCT/US03/18911

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Chowrira et al. Filing Date: October 23, 1993	
		Group: 1645	

*	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <u>Chem. Pharm. Bull.</u> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
*	Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," <u>Biochemical and Biophysical Research Communication</u> 214(2):403-409 (1995)
*	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <u>Tetrahedron Letters</u> 34:301-304 (1993) (sometimes mistakenly referred to as Jschke)
*	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <u>Clinical Chemistry</u> 45:1628-1650 (1999)
*	Jenuwein, "An RNA-Guided Pathway for the Epigenome," <u>Science</u> 297:2215-2218 (2002)
*	Joulliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <u>Fundam. Clin. Pharmacol.</u> 13:16-26 (1999)
*	Joyce et al., "Amplification, mutation and selection of catalytic RNA," <u>Gene</u> 82:83-87 (1989)
*	Joyce, "Directed Molecular Evolution," <u>Scientific American</u> 267:90-97 (1992)
*	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <u>Nature Biotechnology</u> , 23(4):457-462 (2005)
*	Karle et al., "Differential Changes in Induced Seizures After Hippocampal Treatment of Rats with an Antisense Oligodeoxynucleotide to the GABAA Receptor $\gamma 2$ Subunit," <u>Euro. Jour. of Pharmacology</u> 340:153-160 (1997)
*	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <u>Tetrahedron Letters</u> 39:1131-1134 (1998)
*	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
Applicant: Chowrira et al.		Filing Date: October 23, 1993	Group: 1645

*	Koch et al., "Vascular Endothelial Growth Factor," <i>Journal of Immunology</i> 152:4149-4156 (1994)
*	Koike et al., "Thimet Oligopeptidase Cleaves the Full-Length Alzheimer Amyloid Precursor Protein at a β -Secretase Cleavage Site in COS Cells," <i>J. Biochem.</i> , 126, 235-242 (1999)
*	Kronenwett et al., "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset," <i>Blood</i> 91:852-862 (1998)
*	Kumar and Ellington, "Artificial evolution and natural ribozymes," <i>FASEB J.</i> 9:1183-1195 (1995)
*	Kunath et al., "The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice.," <i>Medline (Pharm Res.)</i> 19(6): 810-817 (6/1/2002)
*	Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," <i>Reviews in Molecular Biotechnology</i> 74:27-38 (2000)
*	Kuwabara et al., "Allosterically Controllable Ribozymes with Biosensor Functions," <i>Current Opinion in Chem. Biol.</i> 4:669-677 (2000)
*	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <i>Chemical Reviews</i> 95:2601-2627 (1995)
*	Lasic and Papahadjopoulos, "Liposomes Revisited," <i>Science</i> 267:1275-1276 (1995)
*	Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," <i>ACS Symposium Series</i> 752:184-192 (2000)
*	Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," <i>Glycoconjugates J.</i> 4:317-328 (1987)
*	Lee et al., "Enhancing the Catalytic Repertoire of Nucleic Acids: A Systematic Study of Linker Length and Rigidity," <i>Nucleic Acids Research</i> 29:1565-1573 (2001)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		Chowrira et al.	
		Filing Date:	Group:
		October 23, 1993	1645

*		Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)
*		Lendlein et al., "Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications," <i>Science</i> , 296, 1673-1676 (2002)
*		Lepri et al., "Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization," <i>Journal of Ocular Pharmacology</i> 10:273-281 (1994)
*		Lichner et al., "Double-stranded RNA-binding proteins could suppress RNA interference-mediated antiviral defences," <i>Journal of General Virology</i> , 84, 975-980 (2003)
*		Limbach et al., "Summary: the modified nucleosides of RNA," <u><i>Nucleic Acids Research</i> 22(12):2183-2196 (1994)</u>
*		Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <i>J. Am. Chem. Soc.</i> 120:8531-8532 (1998)
*		Lin et al., "A Novel mRNA-crRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
*		Lin et al., "Human aspartic protease memapsin 2 cleaves the β -secretase site of β -amyloid precursor protein," <i>PNAS</i> , 97, 1456-1460 (2000)
*		Lin et al., "Policing rogue genes," <i>Nature</i> , 402, 128-129 (1999)
*		Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <u><i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)</u>
*		Liu et al., "Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA," <i>Gene Therapy</i> , 6, 1258-1266 (1999)
*		Loakes, "The Applications of Universal DNA Base Analogues," <u><i>Nucleic Acids Research</i> 29:2437-2447 (2001)</u>
*		Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," <u><i>Proc. Natl. Acad. Sci. USA</i> 91:6977-6981 (1994)</u>

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Chowrira et al.	
(Use several sheets if necessary)		Filing Date: October 23, 1993	Group: 1645

*	Ma and Wei, "Enhanced Delivery of Synthetic Oligonucleotides to Human Leukaemic Cells by Liposomes and Immunoliposomes," <i>Leukemia Research</i> 20:925-930 (1996)
*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <i>Biochemistry</i> 32:1751-1758 (1993)
*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <i>Nucleic Acids Research</i> 21:2585-2589 (1993)
*	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> 110:563-574 (2002)
*	Mattick, John S., "The Functional Genomics of Noncoding RNA", <i>Science</i> , 309, 1527-1528 (2005)
*	Matulic-Adamic et al., "Functionalized Nucleoside 5'-triphosphates for In Vitro Selection of New Catalytic Ribonucleic Acids," <i>Bioorganic & Medicinal Chemistry Letters</i> 10:1299-1302 (2000)
*	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <i>Molecular Membrane Biology</i> 16:129-140 (1999)
*	McCaffrey et al., "RNA interference in adult mice," <i>Nature</i> , 148, 38-39 (2002)
*	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <i>Nucleosides & Nucleotides</i> 10:287-290 (1991)
*	McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," <i>RNA</i> 8:842-850 (2002)
*	Mesmaeker et al., "Novel Backbone Replacements for Oligonucleotides," <i>American Chemical Society</i> , pp. 24-39 (1994)
*	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <i>J. Biol. Chem.</i> 268:14514-14522 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
Applicant: Chowrira et al.		Filing Date: October 23, 1993	Group: 1645

	* Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <i>Science</i> 256:992-996 (1992)
	* Mori et al., <i>J. Cellular Physiology</i> , 188, 253-263 (2001)
	* Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," <i>Biochemistry</i> 33:1271-1277 (1994)
	* Noviello et al., "Autosomal Recessive Hypercholesterolemia Protein Interacts with and Regulates the Cell Surface Level of Alzheimer's Amyloid β Precursor Protein," <i>The Journal of Biological Chemistry</i> , 278, 31843-31847 (2003)
	* Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," <i>Cell</i> 107:309-321 (2001)
	* Ohno-Matsui et al., "Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment," <i>Am. J. Pathology</i> , 160, 711-719 (2002)
	* Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <i>Biochimica et Biophysica Acta</i> 1238:86-90 (1995)
	* Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <i>Biochemistry</i> 30:9914-9921 (1991)
	* O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> 79:315-328 (1994)
	* Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," <i>AAPS PharmSci.</i> , 3 (3) article 21 (http://www.pharmsci.org) p. 1- 11 (2001)
	* Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," <i>American Journal of Pathology</i> 137:1243-1252 (1990)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
		Applicant: Chowrira et al.	
		Filing Date: October 23, 1993	Group: 1645

	*	Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localizatin in Drosophila Are Dependent on the RNAi Machinery," <i>Science</i> , 303, 669-672 (2004)
	*	Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced Angiogenesis," <i>Science</i> 268:567-569 (1995)
	*	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)
	*	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)
	*	Passaniti et al., "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Laboratory Investigation</i> 67:519-528 (1992)
	*	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <i>Nature</i> 344:565-567 (1990) (often mistakenly listed as Perrault)
	*	Petersen et al., "Polyethylenimine-graft-Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System, <i>Bioconjugate Chem.</i> , 13, 845-854 (2002)
	*	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> 253:314-317 (1991)
	*	Pierce et al., "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," <i>Proc. Natl. Acad. Sci. USA</i> 92:905-909 (1995)
	*	Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," <i>J. Med. Chem.</i> 24:1388-1395 (1981)
	5.	Prakash et al., "Positional Effect of Chemical Modifications on Short Interference RNA Activity in Mammalian Cells," <i>J. Med. Chem.</i> , 48, 4247-4253 (2005)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		Chowrira et al.	
		Filing Date:	Group:
		October 23, 1993	1645

*	Rajakumar et al., "Effects of Intrastratial Infusion of D2 Receptor Antisense Oligonucleotide on Apomorphine-Induced Behaviors in the Rat," <u>Synapse</u> 26:199-208 (1997)
*	Randall et al., "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs," <u>PNAS</u> , 100, 235-240 (2003)
*	Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," <u>Science</u> 297:1831 (2002)
*	Reinhart et al., "MicroRNAs in Plants," <u>Genes & Development</u> 16:1616-1626 (2002)
*	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <u>J. Am. Chem. Soc.</u> 113:5109-5111 (1991)
*	Saenger (ed), "Modified Nucleosides and Nucleotides; Nucleoside Di- and Triphosphates; Coenzymes and Antibiotics, (ch.7)" <u>Principles of Nucleic Acid Structure</u> 158-200 (1984)
*	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <u>Proc. Natl. Acad. Sci. USA</u> 94:4262-4266 (1997)
*	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <u>Nucl Acids Res.</u> 18:5433-5441 (1990)
*	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <u>Nucleic Acids Research</u> 24:573-581 (1996)
*	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <u>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</u> 23:941-949 (1999) [sometimes cited by RPI as <u>Prog Neuropsychopharmacol Biol Psychiatry</u> 23:941-949, 1999]
*	Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <u>Molecular Cell</u> 10:537-548 (2002)
*	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <u>Nucleic Acids Research</u> 15:3113-3129 (1987)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Chowrira et al.	
(Use several sheets if necessary)			

*	Segarra et al., "Molecular characterization of the <i>Enterococcus faecalis</i> cytolysin activator," <i>Infection and Immunity</i> , 59, 4, 1239-1246 (1991) Database CAPLUS on STN, AN:1992:230597
6.	Semizarov et al., "siRNA-mediated gene silencing: a global genome view," <i>Nucleic Acids Research</i> , 32(13):3836-3845 (2004)
*	Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," <i>Cancer and Metastasis Reviews</i> 12:303-324 (1993)
*	Sethupathy et al., "TarBase: A comprehensive database of experimentally supported animal microRNA targets," <i>RNA</i> , 12:192-197 (2006)
*	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <i>Nucleic Acids Research</i> 19:4247-4251 (1991)
*	Sharp et al., "RNAi and double-strand RNA," <i>Genes & Development</i> , 13:139-141 (1999)
*	Sheehan et al., "Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides," <i>Nucleic Acids Research</i> , 31 (14), 4109-4118 (2003)
*	Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," <i>J. Clin. Invest.</i> 91:2235-2243 (1993)
*	Simantov et al., "Dopamine-Induced Apoptosis in Human Neuronal Cells: Inhibition by Nucleic Acids Antisense to the Dopamine Transporter," <i>Neuroscience</i> 74(1):39-50 (1996)
*	Sommer et al., "The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain," <i>Antisense & Nucleic Acid Drug Development</i> 8:75-85 (1998)
*	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <i>Molecular Biology</i> , Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in <i>Science</i>]
*	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc," <i>Current Opinion in Molecular Therapeutics</i> 2:100-105 (2000)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		Chowrira et al.	
		Filing Date:	Group:
		October 23, 1993	1645

	*	Szostak, "In Vitro Genes," <u>TIBS</u> 17:89-93 (1993)
	*	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> in place of run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <u>Nucleic Acids Research</u> 19:5125-5130 (1991)
	*	Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," <u>Cancer Research</u> 54:4233-4237 (1994)
	*	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection," <u>RNA</u> 3:914-925 (1997)
	*	Thomas et al., "Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells," <u>PNAS</u> , 99, 14640-14645 (2002)
	*	Thomson et al., "Activity of hammerhead ribozymes containing non-nucleotidic linkers," <u>Nucleic Acids Research</u> 21:5600-5603 (1993) (MAY BE REFERRED TO AS THOMPSON)
	*	Turner et al., "Improved Parameters for Prediction of RNA Structure," <u>Cold Spring Harbor Symposia on Quantitative Biology</u> Volume LII, pp. 123-133 (1987)
	*	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <u>J. Am. Chem. Soc.</u> 109:3783-3785 (1987)
	*	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <u>Molecular Interventions</u> , 295, 3, 158-167 (2002)
	*	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <u>Genes & Development</u> 3191-3197 (1999)
	*	Tuschl, "RNA Interference and Small Interfering RNAs," <u>Chembiochem</u> 2:239-245 (2001)
	*	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <u>Proc. Natl. Acad. Sci. USA</u> 96:7053-7058 (1999)
	*	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <u>FEBS Letters</u> 421:280-284 (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Chowrira et al.	
(Use several sheets if necessary)		Filing Date: October 23, 1993	Group: 1645

*	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <u>Chemical Reviews</u> 90:544-584 (1990)
*	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <u>TIBS</u> 17:334-339 (1992)
*	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <u>J. Am. Chem. Soc.</u> 109:7845-7854 (1987)
*	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <u>Nucleic Acids Symposium Series</u> 31:163-164 (1994)
*	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by <i>in Vitro</i> Selection," <u>Biochemistry</u> 36:6495-6501 (1997)
*	Vassar et al., "β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," <u>Science</u> 286:735-741 (1999)
*	Verdel et al., "RNAi-Mediated Targeting of Heterochromatin by the RITS Complex," <u>Science</u> , 303, 672-676 (2004)
*	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <u>Annu. Rev. Biochem.</u> 67:99-134 (1998)
*	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <u>Journal of Biological Chemistry</u> , 278, 7108-7118 (2003)
*	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," <u>Science</u> 297:1833-1837 (2002)
*	Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," <u>Proc. Natl. Acad. Sci. USA</u> , 95, 13959-13964 (1998)
*	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," <u>Nature Cell Biology</u> 2:70-75 (2000)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-A (400/136 CIP1)	Serial No. 10/693,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		Chowrira et al.	
		Filing Date:	Group:
		October 23, 1993	1645

*	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <u>Nucleic Acids Research</u> 23(14):2677-2684 (1995)
*	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <u>Methods in Molecular Biology</u> 74:59-69 (1997)
*	Wu and Wu, "Receptor-mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System," <u>The Journ. of Biol. Chem.</u> 262:4429-4432 (1987)
*	Wu-Pong et al., "Nucleic Acid Drug Delivery, Part 2; Delivery to the Brain," <u>BioPharm</u> 32-38 (1999)
*	Yamada et al., "Nanoparticles for the delivery of genes and drugs to human hepatocytes," <u>Nature Biology</u> , Published online: 29 June 2003, doi:10.1038/nbt843 (August 2003 Volume 21 Number 8 pp 885-890) (2003)
*	Yan et al., "Membrane-anchored Aspartyl Protease with Alzheimer's Disease β -Secretase Activity," <u>Nature</u> 402:533-537 (1999)
*	Yang et al., "Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection," <u>PNAS</u> , 99, 21, 13825-13830 (2002)
*	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <u>Cell</u> 101:25-33 (2000)
*	Zhang et al., "Single Processing Center Models for Human Dicer and Bacterial RNase III," <u>Cell</u> , 118:57-68 (2004)
*	Ziche et al., "Angiogenesis Can Be Stimulated or Repressed <i>In Vivo</i> by a Change in GM3:GD3 Ganglioside Ratio," <u>Laboratory Investigation</u> 67:711-715 (1992)
*	Zinnen et al., "Chemically Modified siRNA: Potential Anti-viral Hepatitis Therapeutics" (Abstract) March 2004

EXAMINER	/Jennifer Pitrak/	DATE CONSIDERED	07/02/2008
----------	-------------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.